Overview

  • Product name

  • Description

    Rabbit polyclonal to Met (c-Met)
  • Host species

    Rabbit
  • Tested applications

    Suitable for: ICC/IF, IHC-P, WBmore details
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Synthetic peptide within Human Met (c-Met) aa 1350 to the C-terminus (C terminal). The exact sequence is proprietary.
    Database link: P08581

  • Positive control

    • A431 cells; Paraffin embedded human breast and ovarian carcinoma tissues.

Properties

Applications

Our Abpromise guarantee covers the use of ab74217 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF Use at an assay dependent concentration. PubMed: 24626333
IHC-P 1/50. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
WB Use a concentration of 2 - 4 µg/ml. Predicted molecular weight: 156 kDa.

Target

  • Function

    Receptor for hepatocyte growth factor and scatter factor. Has a tyrosine-protein kinase activity. Functions in cell proliferation, scattering, morphogenesis and survival.
  • Involvement in disease

    Note=Activation of MET after rearrangement with the TPR gene produces an oncogenic protein.
    Note=Defects in MET may be associated with gastric cancer.
    Defects in MET are a cause of hepatocellular carcinoma (HCC) [MIM:114550].
    Defects in MET are a cause of renal cell carcinoma papillary (RCCP) [MIM:605074]. It is a subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into common renal cell carcinoma (clear cell, non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma.
    Note=A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes.
    Note=MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies.
  • Sequence similarities

    Belongs to the protein kinase superfamily. Tyr protein kinase family.
    Contains 3 IPT/TIG domains.
    Contains 1 protein kinase domain.
    Contains 1 Sema domain.
  • Domain

    The kinase domain is involved in SPSB1 binding.
  • Post-translational
    modifications

    Dephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365.
  • Cellular localization

    Membrane.
  • Information by UniProt
  • Database links

  • Alternative names

    • AUTS9 antibody
    • c met antibody
    • D249 antibody
    • Hepatocyte growth factor receptor antibody
    • HGF antibody
    • HGF receptor antibody
    • HGF/SF receptor antibody
    • HGFR antibody
    • MET antibody
    • Met proto oncogene antibody
    • Met proto oncogene tyrosine kinase antibody
    • MET proto oncogene, receptor tyrosine kinase antibody
    • Met proto-oncogene (hepatocyte growth factor receptor) antibody
    • Met proto-oncogene antibody
    • Met protooncogene antibody
    • MET_HUMAN antibody
    • Oncogene MET antibody
    • Par4 antibody
    • Proto-oncogene c-Met antibody
    • RCCP2 antibody
    • Scatter factor receptor antibody
    • SF receptor antibody
    • Tyrosine-protein kinase Met antibody
    see all

Images

  • ab74217 at 1/50 dilution staining Met (c-Met) in human ovarian carcinoma by Immunohistochemistry, Formalin-fixed, Paraffin-embedded tissue.

References

This product has been referenced in:

  • Du M  et al. MicroRNA-200a suppresses migration and invasion and enhances the radiosensitivity of NSCLC cells by inhibiting the HGF/c-Met signaling pathway. Oncol Rep 41:1497-1508 (2019). Read more (PubMed: 30569179) »
  • Yin L  et al. MicroRNA-365a-3p inhibits c-Rel-mediated NF-?B signaling and the progression of pancreatic cancer. Cancer Lett 452:203-212 (2019). Read more (PubMed: 30910589) »
See all 9 Publications for this product

Customer reviews and Q&As

Question
Answer

Thank you for contacting us.

I have pasted the link to Human Protein Atlas database which shows MET positive staining of various human tissue sections. The red colour represents high staining. You can select positive control section based on this.

http://www.proteinatlas.org/ENSG00000105976/normal

From the left hand menu the Normal or Cancerous tissue sections can be collected.

The 10 minutes primary incubation at 1/50 dilution is for guidelines only, if you are trying antibody at 1/100 or 1/1000 dilution which is not unusual you can try incubating the antibody for 4 hours at 4C or overnight at 4C.

I hope this information is helpful to you. Please do not hesitate to contact us if you need any more advice or information.

Use our products? Submit an Abreview. Earn rewards!
https://www.abcam.com/abreviews

Read More

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up